Cannabinoid Modulation of Pain
Information source: Yale University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pain
Intervention: Thermal (Other); Electrical (Device); Capsaicin (Other)
Phase: Phase 2
Status: Recruiting
Sponsored by: Yale University Official(s) and/or principal investigator(s):
Deepak C D'Souza, M.D., Principal Investigator, Affiliation: Yale University
Overall contact:
Brynn Huguenel, B.A., Phone: 203-932-5711, Ext: 4525, Email: brynn.huguenel@yale.edu
Summary
The purpose of this study is to test the effects of cannabinoids on pain response using a
variety of human experimental pain models.
Clinical Details
Official title: Cannabinoid Modulation of Pain
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research
Primary outcome: Capsaicin-induced hyperalgesia
Secondary outcome: Pain MeasuresNon-pain subjective responses Cognitive subjective responses
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- At least one lifetime exposure to cannabis
- Acceptable Birth Control methods for females
Exclusion Criteria:
- Cannabis naive
- Medical or psychiatric contraindications
- Analgesic medication
- Previous sensitivity to THC or cannabis
Locations and Contacts
Brynn Huguenel, B.A., Phone: 203-932-5711, Ext: 4525, Email: brynn.huguenel@yale.edu
VA Connecticut Healthcare System, West Haven, Connecticut 06516, United States; Recruiting
Brynn Huguenel, B.A., Phone: 203-932-5711, Ext: 4525, Email: brynn.huguenel@yale.edu
Deepak C D'Souza, M.D., Principal Investigator
Additional Information
Starting date: December 2011
Last updated: October 17, 2014
|
